A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer.
Recently, neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil (NAC-DCF) was identified as a novel strong regimen with a high rate of pathological complete response (pCR) in advanced esophageal cancer in Japan. Predicting pCR will contribute to the therapeutic strategy and the prevention...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5685591?pdf=render |
id |
doaj-f72b8268302c407f9c773c0fce894a8c |
---|---|
record_format |
Article |
spelling |
doaj-f72b8268302c407f9c773c0fce894a8c2020-11-25T01:30:48ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-011211e018809810.1371/journal.pone.0188098A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer.Hajime FujishimaShoichi FumotoTomotaka ShibataKohei NishikiYoshiyuki TsukamotoTsuyoshi EtohMasatsugu MoriyamaNorio ShiraishiMasafumi InomataRecently, neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil (NAC-DCF) was identified as a novel strong regimen with a high rate of pathological complete response (pCR) in advanced esophageal cancer in Japan. Predicting pCR will contribute to the therapeutic strategy and the prevention of surgical invasion. However, a predictor of pCR after NAC-DCF has not yet been developed. The aim of this study was to identify a novel predictor of pCR in locally advanced esophageal cancer treated with NAC-DCF.A total of 32 patients who received NAC-DCF followed by esophagectomy between June 2013 and March 2016 were enrolled in this study. We divided the patients into the following 2 groups: pCR group (9 cases) and non-pCR group (23 cases), and compared gene expressions between these groups using DNA microarray data and KeyMolnet. Subsequently, a validation study of candidate molecular expression was performed in 7 additional cases.Seventeen molecules, including transcription factor E2F, T-cell-specific transcription factor, Src (known as "proto-oncogene tyrosine-protein kinase of sarcoma"), interferon regulatory factor 1, thymidylate synthase, cyclin B, cyclin-dependent kinase (CDK) 4, CDK, caspase-1, vitamin D receptor, histone deacetylase, MAPK/ERK kinase, bcl-2-associated X protein, runt-related transcription factor 1, PR domain zinc finger protein 1, platelet-derived growth factor receptor, and interleukin 1, were identified as candidate molecules. The molecules were mainly associated with pathways, such as transcriptional regulation by SMAD, RB/E2F, and STAT. The validation study indicated that 12 of the 17 molecules (71%) matched the trends of molecular expression.A 17-molecule set that predicts pCR after NAC-DCF for locally advanced esophageal cancer was identified.http://europepmc.org/articles/PMC5685591?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hajime Fujishima Shoichi Fumoto Tomotaka Shibata Kohei Nishiki Yoshiyuki Tsukamoto Tsuyoshi Etoh Masatsugu Moriyama Norio Shiraishi Masafumi Inomata |
spellingShingle |
Hajime Fujishima Shoichi Fumoto Tomotaka Shibata Kohei Nishiki Yoshiyuki Tsukamoto Tsuyoshi Etoh Masatsugu Moriyama Norio Shiraishi Masafumi Inomata A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer. PLoS ONE |
author_facet |
Hajime Fujishima Shoichi Fumoto Tomotaka Shibata Kohei Nishiki Yoshiyuki Tsukamoto Tsuyoshi Etoh Masatsugu Moriyama Norio Shiraishi Masafumi Inomata |
author_sort |
Hajime Fujishima |
title |
A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer. |
title_short |
A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer. |
title_full |
A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer. |
title_fullStr |
A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer. |
title_full_unstemmed |
A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer. |
title_sort |
17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2017-01-01 |
description |
Recently, neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil (NAC-DCF) was identified as a novel strong regimen with a high rate of pathological complete response (pCR) in advanced esophageal cancer in Japan. Predicting pCR will contribute to the therapeutic strategy and the prevention of surgical invasion. However, a predictor of pCR after NAC-DCF has not yet been developed. The aim of this study was to identify a novel predictor of pCR in locally advanced esophageal cancer treated with NAC-DCF.A total of 32 patients who received NAC-DCF followed by esophagectomy between June 2013 and March 2016 were enrolled in this study. We divided the patients into the following 2 groups: pCR group (9 cases) and non-pCR group (23 cases), and compared gene expressions between these groups using DNA microarray data and KeyMolnet. Subsequently, a validation study of candidate molecular expression was performed in 7 additional cases.Seventeen molecules, including transcription factor E2F, T-cell-specific transcription factor, Src (known as "proto-oncogene tyrosine-protein kinase of sarcoma"), interferon regulatory factor 1, thymidylate synthase, cyclin B, cyclin-dependent kinase (CDK) 4, CDK, caspase-1, vitamin D receptor, histone deacetylase, MAPK/ERK kinase, bcl-2-associated X protein, runt-related transcription factor 1, PR domain zinc finger protein 1, platelet-derived growth factor receptor, and interleukin 1, were identified as candidate molecules. The molecules were mainly associated with pathways, such as transcriptional regulation by SMAD, RB/E2F, and STAT. The validation study indicated that 12 of the 17 molecules (71%) matched the trends of molecular expression.A 17-molecule set that predicts pCR after NAC-DCF for locally advanced esophageal cancer was identified. |
url |
http://europepmc.org/articles/PMC5685591?pdf=render |
work_keys_str_mv |
AT hajimefujishima a17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer AT shoichifumoto a17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer AT tomotakashibata a17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer AT koheinishiki a17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer AT yoshiyukitsukamoto a17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer AT tsuyoshietoh a17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer AT masatsugumoriyama a17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer AT norioshiraishi a17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer AT masafumiinomata a17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer AT hajimefujishima 17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer AT shoichifumoto 17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer AT tomotakashibata 17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer AT koheinishiki 17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer AT yoshiyukitsukamoto 17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer AT tsuyoshietoh 17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer AT masatsugumoriyama 17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer AT norioshiraishi 17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer AT masafumiinomata 17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer |
_version_ |
1725089803356078080 |